Sermorelin

Sermorelin is a 29-amino acid synthetic analog of GHRH. It was FDA-approved for diagnostic evaluation of growth hormone deficiency in children, but discontinued in the US. It stimulates endogenous GH production with normal pulsatile pattern, unlike exogenous GH which causes continuous elevation.

PubMed results: 21 · Human studies: 14 · Animal studies: 14

Ranges reflect protocols studied in published research and animal-model extrapolation. Presented for research purposes only, not a recommendation or instruction for human use.

FDA-approved dosing (discontinued in US). Based on historical data.

• Subcutaneous Injection — standard range 0.5-1 mg, Once daily at bedtime

6-12 minutes (high confidence)

• NCT00850564 — Effect of Short Term Growth Hormone Releasing Hormone in Healthy Men (NA), status: COMPLETED. Indications: Healthy Volunteers
• NCT00123253 — TH9507 in Patients With HIV-Associated Lipodystrophy (PHASE3), status: COMPLETED. Indications: HIV Infections, Lipodystrophy
• NCT02507245 — Observational Longitudinal Study in Children Affected by Idiopathic Growth Hormone Deficiency (GHD), status: COMPLETED. Indications: Growth Hormone Deficiency
• NCT00000380 — Growth Hormone Releasing Hormone (GHRH) Treatment for Age-Related Sleep Disturbances (NA), status: COMPLETED. Indications: Sleep Disorders
• NCT03018886 — Diagnosing Adult Growth Hormone Deficiency (NA), status: COMPLETED. Indications: Growth Hormone Deficiency
• NCT02092779 — Growth Hormone Deficiency and Empty Sella Cardio-Metabolic Risk Factors in Obesity: a Cross-Sectional Study, status: COMPLETED. Indications: Obesity
• NCT00608023 — TH9507 Extension Study in Patients With HIV-Associated Lipodystrophy (PHASE3), status: COMPLETED. Indications: Lipodystrophy, HIV Infections
• NCT01264497 — Safety Study of TH9507 in Subjects With Stable, Type 2 Diabetes (PHASE2), status: COMPLETED. Indications: Type 2 Diabetes
• NCT01359488 — VRS-317 in Adult Subjects With Growth Hormone Deficiency (PHASE1), status: COMPLETED. Indications: Growth Hormone Deficiency
• NCT00807365 — Six Month Treatment of Growth Hormone Releasing Hormone (GHRH) in the Elderly (PHASE2), status: TERMINATED. Indications: Elderly
• NCT02196831 — Tesamorelin Effects on Liver Fat and Histology in HIV (NA), status: COMPLETED. Indications: Human Immunodeficiency Virus (HIV), Nonalcoholic Fatty Liver Disease (NAFLD), Nonalcoholic Steatohepatitis (NASH)
• NCT01897844 — A Two Part Phase 1, Repeated Doses and Continuous Infusion Study With ITF2984 in Healthy Volunteers (PHASE1), status: COMPLETED. Indications: Healthy
• NCT00006073 — Endocrine Studies in Health and Disease, status: TERMINATED. Indications: Endocrine Diseases
• NCT00448747 — Investigation of a New, Oral Growth Hormone Secretagogue, AEZS-130 as a Growth Hormone Stimulation Test. (PHASE3), status: COMPLETED. Indications: Diagnosis of Adult Growth Hormone Deficiency (AGDH)
• NCT01632592 — Abdominal Obesity, Cardiovascular Inflammation, and Effects of Growth Hormone Releasing Hormone Analogue (NA), status: WITHDRAWN. Indications: Abdominal Obesity
• NCT03226821 — Body Composition and Adipose Tissue in HIV (PHASE4), status: COMPLETED. Indications: HIV Lipodystrophy Syndrome, Growth Hormone Deficiency, Body Composition
• NCT00004332 — Study of the Effect of Growth Hormone-Releasing Hormone Antagonist on Growth Hormone Release in Acromegaly, status: COMPLETED. Indications: Acromegaly
• NCT00638287 — Inter-Assay Growth Hormone and IGF-I Variability, status: WITHDRAWN. Indications: Acromegaly, Growth Hormone Deficiency
• NCT06554717 — Tesamorelin as an Adjunct to Exercise for Improving Physical Function in HIV (PHASE2), status: RECRUITING. Indications: HIV-1-infection, Frailty, Impaired Physical Function, Abdominal Obesity, Aging
• NCT00507104 — Pituitary Functions After Traumatic Brain Injury (TBI) and/or Subarachnoid Hemorrhage (SAH), status: COMPLETED. Indications: Traumatic Brain Injury, Subarachnoid Hemorrhage, Hypopituitarism